Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06615479 · ClinicalTrials.gov registry record · Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

Recruiting
Registry status
Phase 3
Development phase
440
Enrollment target
20
Study locations

NCT06615479: Recruiting Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

NCT06615479 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM) that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 440 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06615479, a Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM), is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

RECRUITING
Registry status
Phase 3
Development phase
440 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Conditions Studied

Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG Daratumumab
  • DRUG Pomalidomide
  • DRUG BMS-986393

Study Locations (20)

Florida

  • Baptist MD Anderson Cancer Center - Jacksonville
  • Local Institution - 0130 - Miami
  • Local Institution - 0228 - Orlando

California

  • UCLA Hematology/Oncology - Santa Monica - Los Angeles
  • Local Institution - 0050 - Orange

New York

  • Local Institution - 0229 - New York
  • Local Institution - 0221 - Stony Brook

North Carolina

  • Local Institution - 0067 - Charlotte
  • Local Institution - 0216 - Winston-Salem

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia
  • Local Institution - 0232 - Pittsburgh

Alabama

  • University of Alabama at Birmingham - Birmingham

District of Columbia

  • Local Institution - 0223 - Washington D.C.

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 440 participants
Start Date 2025-03-12
Est. Completion 2032-06-22
Phase Phase 3
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

14 total trials

What NCT06615479 shows while recruiting

NCT06615479 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).

The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma (RRMM) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT06615479 names 20 study sites across 14 states, led by Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT06615479 about?

NCT06615479 is a clinical study titled "A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)". The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

What is the current status of trial NCT06615479?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2025-03-12. Estimated completion is 2032-06-22.

What conditions does trial NCT06615479 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma (RRMM).

What interventions are being tested in trial NCT06615479?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), BMS-986393 (DRUG).

Who is sponsoring clinical trial NCT06615479?

This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06615479 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT06615479's enrollment target sits among peer trials

440 868th of 2000 higher than 1,129 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05114538 · 440 participants · NA

    Improving the Part C Early Intervention Service Delivery System for Children with ASD

  • NCT05117619 · 440 participants · NA

    The HOME Program for Individuals With Traumatic Brain Injury and Family Members

  • NCT05602194 · 440 participants · Phase 3

    Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  • NCT05624879 · 440 participants · NA

    Accelerated Resolution Therapy for Early Maladaptive Grief

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06615479

Source: ClinicalTrials.gov NCT06615479, the US trial registry maintained by the National Library of Medicine. NCT06615479 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.